4th Annual Chair Summit - Master Class for Neuroscience Professional Development
neuroscienceCME Medical Meeting
Symposium Dates: June 23-26, 2011This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
- Pharmacists (ACPE)
- Physical Therapists
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, June 23, 2012
Note: Credit Is No Longer Available
| announcement forthcoming, |
Co-provided by
To collaboratively evaluate evidence, engage in peer-to-peer learning, and apply evidence to practice to develop individualized management strategies for improved outcomes for patients with psychiatric and neurologic disorders.
At the end of this CE activity, participants should be able to:
- Integrate the latest research and clinical data in psychiatric and neurologic disorders and translate into daily clinical practice.
- Engage in discussion with experts and colleagues about clinical challenges in your practice and apply new insights and data to improve measurement-based patient care.
- Develop a personal action plan that integrates 3 new evidence-based concepts that will improve clinical performance and patient outcomes.
This continuing education activity is supported by educational grants from various organizations.
The Pain Track for this activity is supported by an educational grant from Endo Pharmaceuticals.
USF Health and CME Outfitters, LLC, gratefully acknowledge an educational grant from Genentech in support of this CE activity.
The Schizophrenia Track for this activity is supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
The Alzheimer's Track for this activity is supported by an educational grant from Pfizer Inc.
This educational activity is supported by an independent medical educational grant from Shire.
The Schizophrenia and Bipolar Disorder Tracks for this activity are supported by an educational grant from Sunovion Pharmaceuticals Inc.
The Sleep-Wake Disorders Track for this activity is supported by an educational grant from UCB.
Physicians, physician assistants, nurse practitioners, nurses, social workers, certified case managers, pharmacists, psychologists, physical therapists, and other healthcare professionals with an interest in mental health.
CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
USF Health designates this live activity for a maximum of 23.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 23 contact hours.
CEP Credit (Psychologists):
CME Outfitters is approved by the American Psychological Association to sponsor continuing education for psychologists. CME Outfitters maintains responsibility for this program and its content. (23 CE credits)
NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 23 continuing education contact hours.
CCMC Credit (Certified Case Managers):
This program has been approved for 23 hours by the Commission for Case Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 23 contact hours (2.3 CEUs)
Universal Program Number: 0376-9999-11-004-L01-P
Activity Type: knowledge-based
Disclosure Declaration
CME Outfitters, LLC, reserves the right to update the list of faculty or make necessary changes in names, titles, affiliations, and other details without notice.
USF Health and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of USF Health and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
Dr. Biller has no disclosures to report.
Dr. Frye has disclosed that he receives grant support from the Mayo Foundation for Medical Education and Research; National Alliance for Schizophrenia and Depression (NARSAD); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Mental Health (NIMH); and Pfizer Inc. He serves as a consultant to Merck & Co., Inc. and Sunovion Pharmaceuticals Inc.
Dr. Gleason has no disclosures to report.
Dr. Gold has no disclosures to report.
Dr. Hirschfeld has disclosed that he receives honoraria from the Merck Manual Editorial Board. He receives royalties from Taylor and Francis Group, and Jones and Bartlett Publishers.
Dr. Kalin has disclosed that he serves on the advisory boards of CeNeRx BioPharma; CME Outfitters, LLC; Corcept Therapeutics; Elsevier; Janssen L.P.; and Letters & Sciences. He is a stockholder of/has equity options in CeNeRx BioPharma and Corcept Therapeutics. Dr. Kalin is the owner of Promoter Neurosciences, LLC, and holds patents for the following: promoter sequences for corticotropin-releasing factor CRF2alpha and method of identifying agents that alter the activity of the promoter sequences (U.S. Patent issued on 07-04-06; patent #7071323, U.S. Patent issued on 05-12-09; patent #7,531,356); promoter sequences for urocortin II and the use thereof (U.S. Patent issued on 08-08-06; patent #7087385); and promoter sequences for corticotropin-releasing factor binding protein and use thereof (U.S. Patent issued on 10-17-06; patent #7122650).
Dr. Kay has disclosed that he receives financial or material support from England for Books and John R. Wiley and Sons, Inc.
Dr. Keller has disclosed that he serves as a consultant for Medtronic, Inc.
Dr. Krishnan has disclosed that he serves as a consultant to CeNeRx BioPharma, Inc.; Corcept Therapeutics; Eisai Inc.; Lundbeck Research USA, Inc.; Orexigen Therapeutics, Inc.; and Sonexa Therapeutics, Inc.
Dr. Kumar has disclosed that he receives grants/research support from the National Institutes of Health. He also serves as the Associate Editor of the American Journal of Geriatric Psychiatry.
Dr. Lieberman has disclosed that he receives grants/research support from Allon Therapeutics, F. Hoffmann-La Roche LTD, GlaxoSmithKline, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Sepracor Inc., and Targacept, Inc. He serves as a consultant to Bioline, GlaxoSmithKline, Intra-Cellular Therapies, Inc., Lilly USA, LLC, Pierre Fabre Laboratories, and PsychoGenics, Inc. He holds a patent from Repligen Corporation.
Dr. Malone has disclosed that he receives grants/research support from Medtronic, Inc. He serves on the speakers bureau of Bristol-Myers Squibb.
Dr. McCall has disclosed that he receives grants/research support from Cephalon, Inc., and Mini Mitter. He serves on the advisory boards of Merck & Co., Inc, Sealy Corporation, and Sepracor Inc., and on the speakers bureaus of Merck & Co., Inc., and Sepracor Inc.
Dr. Miller has no disclosures to report.
Dr. Nemeroff has disclosed that he receives grants/research support from the Agency for Healthcare Research and Quality (AHRQ) and the National Institutes of Health (NIH). He serves as a consultant to Takeda Pharmaceuticals North America, Inc., and Xhale, Inc. He serves on the advisory boards of the American Foundation for Suicide Prevention (AFSP), the Anxiety Disorders Association of America (ADAA), CeNeRx BioPharma, the National Alliance for Research on Schizophrenia and Depression (NARSAD), NovaDel Pharma, Inc., and PharmaNeuroBoost. He serves on the board of directors of the American Foundation for Suicide Prevention and NovaDel Pharma, Inc. He is a stockholder of CeNeRx BioPharma, Corcept Therapeutics, NovaDel Pharma, Inc., PharmaNeuroBoost, Reevax Pharmaceuticals LLC, and Xhale, Inc. His other financial Interests include CeNeRx BioPharma and PharmaNeuroBoost. He holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Dr. Racke has disclosed that he receives grants from the National Institutes of Health and the National Multiple Sclerosis Society. He serves as a consultant to Biogen Idec and Eli Lilly and Company. He serves on the advisory board of Novartis Pharmaceuticals Corporation. He serves on the editorial boards of Archives of Neurology, Journal of Neuroimmunology, and The Neurologist.
Dr. Rogawski has disclosed that he receives grants from Congressionally Directed Medical Research Programs; Epilepsy Research Foundation (Epilepsy Foundation); National Institute of Neurological Disorders and Stroke; and People Against Childhood Epilepsy, Inc. He receives research support from Eisai Inc.; Forest Research Institute, Inc.; and Gilead Sciences, Inc. He serves as a consultant to Eli Lilly and Company; GlaxoSmithKline; Merck & Co., Inc.; Novartis Corporation; and Pfizer Inc.
Dr. Rubinow has no disclosures to report.
Dr. Schatzberg has disclosed that he serves as a consultant to BrainCells Inc.; CeNeRx BioPharma; Jazz Pharmaceuticals, Inc.; Neuronetics Inc.; NovaDel Pharma; PharmaNeuroBoost; Sanofi-aventis; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceuticals North America, Inc. He has equity in the following companies: Amnestix, Inc.; BrainCells Inc.; CeNeRx BioPharma; Corcept Therapeutics; Forest Laboratories, Inc.; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; NovaDel Pharma; Pfizer Inc.; PharmaNeuroBoost; Somaxon; and Synosis. He is the named inventor on pharmacogenetic and antiglucocorticoid use patents on prediction of antidepressant response.
Dr. Scheffer has disclosed that he has received grants for the Collaborative Lithium Trial (CoLT) and Sub-contracted PI NICHD. He receives research support from Bristol-Myers Squibb Company; Pfizer Inc.; and Wyeth Pharmaceuticals.
Dr. Schulz has disclosed that he receives grants/research support from AstraZeneca Pharmaceuticals LP, Otsuka America Pharmaceutical, Inc., and Rules-Based Medicine, Inc. He serves as a consultant to Biovail Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Lilly USA, LLC.
Dr. Silverman has no disclosures to report.
Dr. Summergrad has disclosed that he receives grants/research support from the Arthur Vining Davis Foundation and the Schwartz Center. He serves as a consultant to American Well Inc.
Dr. Ulzen has no disclosures to report.
Dr. Weinberger has no disclosures to report.
Dr. Ziedonis has no disclosures to report.
Disclosures were obtained from the planning committee members and are on file in the USF Health Office of Continuing Professional Development (OCPD) for review. Disclosures were obtained from the USF Health OCPD staff: Nothing to Disclose.
Howard Bliwise, MD (peer/content reviewer) has no disclosures to report.
Christina Ansted, MPH, CCMEP (planning committee) has no disclosures to report.
Monique Johnson, MD, CCMEP (planning committee) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Joy Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Discussion of Off-Label Use: Because this course is meant to educate physicians with what is currently in use and what may be available in the future, there may be “off-label” use discussed in the presentations. Speakers have been requested to inform the audience when off-label use is being discussed.
Accommodations for Disabilities: Please notify Jamie Conte at jconte@cmeoutfitters.com or call 877.263.7767 a minimum of 10 working
days in advance of the event if a reasonable accommodation for a disability is needed.
Equal Opportunity Statement: Events, activities, programs and facilities of the University of South Florida are available to all without regard to race, color, marital status, gender, sexual orientation, religion, national origin, disability, age, Vietnam or disabled veteran status as provided by law and in accordance with the university’s respect for personal dignity.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MM-031-062311-90
